Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas
Open Access
- 20 July 2011
- journal article
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 9 (1) , 17
Abstract
More than 40 years have passed since Kawasaki syndrome (KS) was first described. Yet KS still remains an enigmatic illness which damages the coronary arteries in a quarter of untreated patients and is the most common cause of childhood-acquired heart disease in developed countries. Many gaps exist in our knowledge of the etiology and pathogenesis of KS, making improvements in therapy difficult. In addition, many KS features and issues still demand further efforts to achieve a much better understanding of the disease. Some of these problem areas include coronary artery injuries in children not fulfilling the classic diagnostic criteria, genetic predisposition to KS, unpredictable ineffectiveness of current therapy in some cases, vascular dysfunction in patients not showing echocardiographic evidence of coronary artery abnormalities in the acute phase of KS, and risk of potential premature atherosclerosis. Also, the lack of specific laboratory tests for early identification of the atypical and incomplete cases, especially in infants, is one of the main obstacles to beginning treatment early and thereby decreasing the incidence of cardiovascular involvement. Transthoracic echocardiography remains the gold-standard for evaluation of coronary arteries in the acute phase and follow-up. In KS patients with severe vascular complications, more costly and potentially invasive investigations such as coronary CT angiography and MRI may be necessary. As children with KS with or without heart involvement become adolescents and adults, the recognition and treatment of the potential long term sequelae become crucial, requiring that rheumatologists, infectious disease specialists, and cardiologists cooperate to develop specific guidelines for a proper evaluation and management of these patients. More education is needed for physicians and other professionals about how to recognize the long-term impact of systemic problems related to KS.Keywords
This publication has 80 references indexed in Scilit:
- Transforming Growth Factor-β Signaling Pathway in Patients With Kawasaki DiseaseCirculation: Cardiovascular Genetics, 2011
- Noncoronary Cardiac Abnormalities Are Associated With Coronary Artery Dilation and With Laboratory Inflammatory Markers in Acute Kawasaki DiseaseJACC, 2011
- Prospective Open-Label Trial of Etanercept as Adjunctive Therapy for Kawasaki DiseaseThe Journal of Pediatrics, 2010
- Pathogenesis and management of Kawasaki diseaseExpert Review of Anti-infective Therapy, 2010
- Performance of 2004 American Heart Association Recommendations for Treatment of Kawasaki DiseasePediatrics, 2010
- A Genome-Wide Association Study Identifies Novel and Functionally Related Susceptibility Loci for Kawasaki DiseasePLOS Genetics, 2009
- Infliximab Treatment of Intravenous Immunoglobulin–Resistant Kawasaki DiseaseThe Journal of Pediatrics, 2008
- RNA-Containing Cytoplasmic Inclusion Bodies in Ciliated Bronchial Epithelium Months to Years after Acute Kawasaki DiseasePLOS ONE, 2008
- Low-dose Methotrexate Therapy for Intravenous Immunoglobulin-resistant Kawasaki DiseaseYonsei Medical Journal, 2008
- Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki diseaseThe Journal of Pediatrics, 1991